WinSanTor, Inc.

SAN DIEGO, CA · Biotech · Private

Small molecule therapeutics for peripheral neuropathies targeting nerve regeneration and pain signaling

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · winsantor.com

Sector: Biotech
Headquarters: SAN DIEGO, CA
Latest Form D: $783K, Nov 2017
Total capital: $12.5M

Federal grants: $11.7M; 13 awards · 2015–2022; Rank in peer group#39 of 514
Private capital raised: $783K; 1 Form D · last Nov 2017; 107 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 6 pending

Capital timeline

Latest events

Aug 2022Federal grantHealth and Human S · Phase II · Clinical investigation of topical delivery of a muscarinic receptor antagonist for the prevention of chemotherapy-induced peripheral neuropathy$899K
Sep 2021Federal grantHealth and Human S · Phase II · Clinical investigation of topical delivery of a muscarinic receptor antagonist for the prevention of chemotherapy-induced peripheral neuropathy$1.1M
Mar 2021Federal grantHealth and Human S · Phase II · Regeneration of Epidermal Nerves in Human Diabetic Neuropathy$985K
Sep 2020Federal grantHealth and Human S · Phase I · Development of a topical fixed-dose combination drug for peripheral neuropathic pain.$699K
May 2020Federal grantHealth and Human S · Phase II · Regeneration of Epidermal Nerves in Human Diabetic Neuropathy$996K
Aug 2019Federal grantHealth and Human S · Phase II · Development of Pirenzepine for CIPN$1.4M
Apr 2019Federal grantHealth and Human S · Phase II · Regeneration of Epidermal Nerves in Human Diabetic Neuropathy$1M
Nov 2017Private capital raisedForm D · SEC · 1st filing$783K

Show 6 earlier federal awards

Sep 2018Federal grantHealth and Human S · Phase II · Development of Pirenzepine for CIPN$2M
Sep 2017Federal grantHealth and Human S · Phase I · Development of Pirenzepine for HIV-SN$466K
May 2017Federal grantHealth and Human S · Phase I · Development of Pirenzepine for CIPN$299K
Jul 2016Federal grantHealth and Human S · Phase II · Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy$592K
Apr 2016Federal grantHealth and Human S · Phase II · Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy$300K
Jun 2015Federal grantHealth and Human S · Phase II · Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy$987K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

29months

from WinSanTor, Inc.’s first federal award to its first private round.

First federal award · Jun 2015: Health and Human S · $987K
First Form D · Nov 2017: $783K · 1st Form D
Awards before first raise: 5 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#39 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Nigel CalcuttDirectorNamed in SEC Form D filings
Stan KimExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6

Oct 31, 2024PendingCompositions And Methods For Improving Sexual Sensory DisordersUSPTOApplication 18767228
Sep 1, 2022PendingTopical Formulations For Treatment Of Peripheral NeuropathiesUSPTOApplication 17593792
PendingCompositions And Methods For Improving Sexual Sensory DisordersUSPTOApplication PCTUS2023010665

Show all 6 patent records

Compositions And Methods For Improving Sexual Sensory DisordersOct 31, 2024 · Application 18767228Pending
Topical Formulations For Treatment Of Peripheral NeuropathiesSep 1, 2022 · Application 17593792Pending
Compositions And Methods For Improving Sexual Sensory DisordersApplication PCTUS2023010665Pending
Compositions And Methods For Improving Sexual Sensory DisordersApplication 63300008Pending
Topical Formulations For Treatment Of Peripheral NeuropathiesApplication PCTUS2020024504Pending
Topical Formulations For Treatment Of Peripheral NeurapathiesApplication 62824060Pending

ACCURIUS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Goldilocks Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
ALLANDER BIOTECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
Kioga Inc.Similar federal contract value in Biotech · null in contracts
ZENA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
SYNLIFE INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.